Abstract: An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis, and includes instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops the aqueous ophthalmic composition described.

Abstract: An aqueous ophthalmic composition comprises a carboxy-containing polyanionic polymer that has a viscosity in the range from about 300 cp to about 1500 cp outside the eye and a total concentration of cations of less than about 50 mM, wherein the viscosity of the composition does not increase when the composition comes into contact with surface ocular fluid.

Abstract: An ophthalmic treatment system comprises an ophthalmic treatment solution and a biguanide antimicrobial agent in solid form and in contact with said treatment solution such as to inhibit bacterial and/or fungal growth in said solution. The biguanide is partially or wholly terminated with an amine compound.

Abstract: A method for improving the integrity of the corneal epithelium by introducing into the eye an effective amount of a ophthalmically compatible retinoid sufficient to enhance the integrity of the corneal epithelium.

Abstract: A method for improving the integrity of the corneal epithelium by introducing into the eye an effective amount of a ophthalmically compatible retinoid sufficient to enhance the integrity of the corneal epithelium.

Abstract: A method for improving the integrity of the corneal epithelium by introducing into the eye an effective amount of a ophthalmically compatible retinoid sufficient to enhance the integrity of the corneal epithelium.

Abstract: The invention provides an ophthalmic aqueous composition for topical administration, comprising: (a) a block copolymer of propylene oxide and ethylene oxide in concentration sufficient to provide viscosity of less than about 25 centipoise at ambient temperature and viscosity of from about 25 to about 55 centipoise when applied topically to a patient; (b) hydroxypropyl methylcellulose in concentration sufficient to improve the durability of the gel formed by the block copolymer. The invention further provides a method for administering ophthalmic pharmaceuticals.

Abstract: The invention provides a method for inhibiting the binding of a biguanide antimicrobial in aqueous solution to a hydrogel in contact with said solution comprising providing in said solution an amount of cyclodextrin sufficient to inhibit sorption of the biguanide antimicrobial to a hydrogel.

Abstract: The invention provides a method for inhibiting the binding of a biguanide antimicrobial in aqueous solution to a hydrogel in contact with said solution comprising providing in said solution an amount of cyclodextrin sufficient to inhibit sorption of the biguanide antimicrobial to a hydrogel.

Abstract: The invention provides a method for inhibiting the binding of a biguanide disinfectant in aqueous solution to a poly(ethylene) solid in contact with said solution comprising providing in said solution an amount of cyclodextrin sufficient to inhibit binding of the biguanide disinfectant to the poly(ethylene) solid.

Abstract: The present invention provides an optically clear, hydrophilic coating upon the surface of a non-plasma treated hydrophobic hydrogel lens by heating the lens in an aqueous solution containing a surface-protective agent. Alternately, the non-plasma treated hydrophobic hydrogel lens may be subjected to ultrasonication while immersed in an aqueous solution containing a surface-protective agent.

Abstract: A method for improving the integrity of the corneal epithelium by introducing into the eye an effective amount of a ophthalmically compatible retinoid sufficient to enhance the integrity of the corneal epithelium.

Abstract: The invention provides an ophthalmic aqueous composition for topical administration, comprising:

Abstract: The present invention is directed to a method of treating dry eye by instilling eyedrops of a composition containing a cationic cellulosic polymer. Such compositions have been found to alleviate the symptoms of dry eye without requiring the presence of anionic therapeutic agents. Low ionic strength solutions are particularly preferred.

Abstract: This invention relates to compositions comprising pheniramine. In particular, it has been found that pheniramine in combination with n effective amount of a povidone provides improved comfort and reduces the symptoms of dryness compared to compositions with pheniramine alone.

Abstract: The present invention is directed towards a method, a composition and an article of manufacture for protecting the skin from jellyfish stings. The method comprises topically contacting the skin with a composition containing polymeric quaternary ammonium salt in amounts sufficient to protect against the rupture of jellyfish nematocysts. The composition can be in the form of an emulsion, liquid dispersion, solution, skin cream, face cream, lotion or ointment.

Abstract: A process and composition for inhibiting surfactant irritation and insult comprising an aqueous solution of a surfactant and an effective amount of an irritation inhibitor selected from the group consisting of lecithin, sodium cetearyl sulfate, an amino acid, cocamine compounds, amine oxides, glyceryl monoesters, ethoxylated monocarboxylic acids, ethoxylated hydroxyl compounds and mixtures thereof.

Abstract: A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen hydroxy. The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals. Benzyl paraben, benzyl salicylate and benzyl benzoate are preferred.

Abstract: A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or lower alkyl C.sub.1-8. The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals; preferably, R.sub.1 amd R.sub.2 are both methyl.

Abstract: A non-steroidal anti-inflammatory composition comprising an active anti-inflammatory agent having the formula: ##STR1## wherein R is ##STR2## The active agent is formulated with a pharmaceutically acceptable carrier for use in the treatment of pain, inflammation and other related symptoms on mammals. Benzylcinnamate and dibenzalacetone are preferred.